Original Article
DOI: https://doi.org/10.70749/ijbr.v4i4.2928

INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://ijbr.com.pk
ISSN: 2960-2793/ 2960-2807

Exploiting Plant-Based Nanostructures for Cancer Theranostics: Mechanistic Advances, Phytobiological Challenges, and Future Pathways

Rabia Iqbal[1], Shumaila Rasheed[2], Rimsha Abdul Razzaq[3], Sadaf Mehfooz[2], Kinza Imtiaz[2], Fiza Fatima[2]

[1]Department of Biochemistry and Biotechnology, University of Gujrat, Gujrat, Punjab, Pakistan.
[2]Department of Botany, Government College University Lahore, Katchery Road, Lahore, Punjab, Pakistan.
[3]Institute of Botany, University of the Punjab, Lahore, Punjab, Pakistan.

ARTICLE INFO

Keywords: Green synthesis, Phytonanomedicine, Precision oncology, Theranostic, Tumor heterogeneity, Tumor targeting.

Correspondence to: Rabia Iqbal, Department of Biochemistry and Biotechnology, University of Gujrat, Gujrat, Punjab, Pakistan.
Email: rabiaaiqbal123@gmail.com

Declaration
Authors' Contribution
All authors equally contributed to the study and approved the final manuscript

Conflict of Interest: No conflict of interest.

Funding: No funding received by the authors.

Article History
Received: 01-02-2026 Revised: 16-04-2026
Accepted: 20-04-2026 Published: 26-04-2026

ABSTRACT

Cancer, a leading cause of global mortality, necessitates innovative therapeutic strategies beyond conventional modalities. Phytonanomedicine, which harnesses plant extracts for the green synthesis of multifunctional nanoparticles, represents a promising theranostic platform. This approach leverages phytochemicals as reducing and stabilizing agents to fabricate a diverse taxonomy of metallic, metal oxide, and hybrid nanostructures. The inherent biocompatibility and eco-friendliness of this method are coupled with the ability to engineer key physicochemical properties including size, shape, surface charge, and functionalization to dictate biological fate. These engineered nanoparticles function as integrative theranostic systems, enabling precision tumor imaging through modalities like MRI and photoacoustics, and delivering multimodal therapies via drug delivery, photothermal action, and intrinsic bioactivity. However, their journey from administration to action is governed by a complex in vivo odyssey involving circulation, targeting (passive EPR effect and active ligand strategies), cellular uptake, and clearance. Despite significant promise, the field faces a critical translational chasm marked by challenges in reproducible synthesis, a complex and dynamic protein corona, ambiguous regulatory pathways, and biological barriers like tumor heterogeneity. To bridge this gap, future trajectories must pioneer next-generation, stimuli-responsive nanoplatforms, converge with AI and omics for rational design, and move toward personalized medicine through biomarker integration. Ultimately, the sustainable clinical translation of phytonanomedicines requires a cohesive roadmap that marries green chemistry principles with robust manufacturing and innovative clinical trial designs, positioning plant-derived nanotherapeutics as a viable paradigm for next-generation oncology.

1. INTRODUCTION

Cancer is the uncontrolled proliferation of a healthy cell that creates genetic abnormalities and alterations which accumulate within cells and tissues, leading to tumorigenesis (Iqbal et al., 2017; Sargazi et al., 2022). Indeed, this disease is a malignant tumor with a high death rate, and millions of people worldwide die each year from various varieties of cancer (Leng et al., 2018). According to World Health Organization (WHO), lung cancer now ranks sixth among the leading causes of death globally (WHO, 2019). The occurrence of cancer is also associated with environmental factors, including air pollution, exposure to chemical pesticides, heavy metals, radiation, and infectious agents (Hussain et al., 2018; Sargazi et al., 2022).

The nanotechnology applied to cancer diagnosis and treatment emerged as a promising alternative with the potential of successfully combining the advances made at the nanoscale with cellular and molecular components that may allow overcoming the physiological and technological limits of conventional cancer treatment modalities (Tinajero-Diaz et al., 2021). This approach has facilitated the coupling of nanoparticles (NPs) synthesized via the green biological pathway with target molecules, allowing an efficient interaction with biological systems (Stephen et al., 2020). In most cases, NPs are part of a complex multishell cancer cell targeting delivery system that serves as antineoplastic drug nanocarrier (Stylianopoulos & Jain, 2015). However, NPs alone are able to work as cytotoxic agents because, due to their physicochemical properties, they tend to accumulate passively into the tumoral tissue (Kashkooli et al., 2020; Kashkooli et al., 2021). Cytotoxic agents (drugs, encapsulated drugs, or NPs) can be released from the carrier to the bloodstream or from the carrier directly into the tumor. In both cases, adsorption of plasma and interactions with the surrounding tissues occur until their

metabolization and clarification (Kashkooli et al., 2020). As expected, NPs must cross several physiological barriers to reach cancer cells. Many physical, chemical, and biological phenomena are involved during the NPs and physiological barrier encountering, e.g., interactions with proteins, cells, and the dynamics of NPs from the blood to the tumor, etc., which significantly modify the behavior and effect of NPs (Lane et al., 2020; Tinajero-Diaz et al., 2021).

Recently, researchers are concentrating in the design and development of most efficient and eco-friendly green chemistry method for the synthesis of metal nanoparticles (Mukherjee et al., 2013; Mukherjee et al., 2014; Patra et al., 2015). Among several methods available in the literature, green synthesis approach for the synthesis of metal nanoparticles has several advantages over conventional methods such as it (i) is very simple, clean & efficient, (ii) is eco-friendly & economically cheap as we use bio-resources (plants, fungi, algae, microorganism) that can help as reducing agent as well as stabilizing agent & capping agent, (iii) needs ambient temperature and pressure, (iv) is a non-toxic method due to very less or non- consumption of hazardous materials on the surface of nanomaterials, (v) does not need any external ligand or capping or stabilizing agent for nanoparticles, and (vi) is a low cost method due to minimum or non-requirement of energy (Lee et al., 2011; Mukherjee et al., 2012; Mukherjee et al., 2014). Moreover, biosynthesized nanoparticles are mostly biocompatible and highly applicable for biomedical applications (Mukherjee et a., 2013; Patra et al., 2015). In the present report, we demonstrate the green chemistry approach for the synthesis of gold and silver nanoparticles using '*Butea monosperma* (BM)' leaf extract where BM leaves act as both reducing as well as stabilizing agent/capping agent. This plant is popular as Ayurvedic herb in India as it shows antibacterial, antifungal, hypoglycemic and anti-inflammatory activities (Patra et al., 2015).

2. The Phyto-Nanofabrication Arsenal: Synthesis, Classification, and Tunability

This section delves into the foundational principles of using plant systems as nanofactories. It moves beyond the simple "green synthesis" narrative to establish a structured understanding of the phytochemical arsenal, the diverse nanomaterials it can produce, and the strategic engineering of their properties for desired biological applications.

2.1. Foundations of Green Nanosynthesis: Phytochemicals as Reductive and Structuring Agents

The reduction of metal ions (e.g., Au^{3+}, Ag^{+}, Zn^{2+}) is not a singular event but a cascade driven by a complex phytochemical repertoire. Key classes include polyphenols (e.g., flavonoids, tannins) and terpenoids, which act as potent reducing agents via their hydroxyl and carbonyl groups, donating electrons to metal ions (Mittal et al., 2013). Simultaneously, proteins, amino acids, and polysaccharides present in the extract serve as capping and stabilizing agents, binding to the nascent nanoparticle nuclei to control growth, prevent aggregation, and confer biological compatibility (Kharissova et al., 2013). This dual function reduction and stabilization is what distinguishes phyto-nanofabrication, where the extract is a multi-functional "green reagent" that dictates the reaction kinetics and final surface chemistry. The choice of plant part (leaf, root, fruit, seed), extraction solvent, and reaction conditions (pH, temperature) directly influences the type and concentration of these active phytochemicals, thereby offering a primary lever for tunability (Makarov et al., 2014).

2.2. A Taxonomy of Plant-Derived Nanostructures: From Metallic Cores to Hybrid Organic Frameworks

The phyto-synthesis platform is remarkably versatile, yielding a wide taxonomy of nanostructures:

- **Metallic Nanoparticles:** The most reported category, including noble metals like silver (AgNPs) with antimicrobial properties and gold (AuNPs) for diagnostics and drug delivery, as well as transition metals like zinc oxide (ZnO NPs) and iron oxide (Fe_3O_4 NPs) (Ahmed et al., 2016).
- **Metal Oxide Nanoparticles:** Formed from the oxidation of synthesized metal nuclei or direct precipitation, such as TiO_2 and CuO NPs.
- **Bimetallic/Alloy Nanoparticles:** Combining two metals (e.g., Au-Ag, Fe-Pt) using co-reduction, often exhibiting enhanced catalytic or magnetic properties due to synergistic effects (Khan et al., 2019).
- **Selenium and Tellurium Nanoparticles:** Valued for their antioxidant and anticancer activities, synthesized using plant phenolic acids and proteins.
- **Carbon-Based Nanomaterials:** Emerging reports on the synthesis of quantum dots and graphene analogues using plant sugars and cellulose as carbon sources (Verma et al., 2022).
- **Hybrid and Composite Frameworks:** This advanced class involves the integration of phyto-synthesized inorganic cores with organic matrices (e.g., chitosan, algal polymers) or the formation of nanostructures directly on biological templates, creating materials with multifunctional capabilities (Garg et al., 2021).

Figure 1.

A schematic taxonomy of plant-derived nanostructures synthesized via phyto-mediated routes, illustrating major classes including metallic, metal oxide, bimetallic/alloy, selenium/tellurium, carbon-based, and hybrid nanomaterials, along with their synthesis pathways and multifunctional applications



2.3. Engineering Function through Form: Controlling Physicochemical Determinants of Biological Fate

The biological efficacy and pharmacokinetics of nanoparticles are governed by their physicochemical

properties, which can be engineered during phyto-synthesis:

Size & Shape Control: Smaller nanoparticles (< 50 nm) typically exhibit higher cellular uptake and surface reactivity. The phytochemical profile can be tuned to yield spheres, rods, triangles, or wires; for instance, high tannin content often favors anisotropic growth (Ahmad et al., 2019).

Surface Charge (Zeta Potential): A critical determinant of colloidal stability and interaction with negatively charged cell membranes. Extracts rich in anionic compounds (e.g., organic acids) yield highly negative zeta potentials, enhancing stability, while amine-rich extracts can produce more neutral or positive surfaces (Siddiqi et al., 2018).

Surface Functionalization: The inherent "green corona" of phytochemicals (e.g., proteins, polyphenols) adsorbed on the nanoparticle surface dictates its biological identity. This corona can be modulated for stealth properties, targeted delivery (by conjugating specific ligands), or enhanced biocompatibility. For example, the inherent antioxidant properties of the corona can augment the therapeutic profile of the core material (Fratoddi et al., 2018).

Crystallinity: Reaction temperature and time influence the degree of crystallinity, which affects catalytic activity, dissolution rate, and mechanical strength. Slower biosynthesis at moderate temperatures often yields highly crystalline structures (Iravani, 2011).

By strategically manipulating synthesis parameters including the plant source, extract concentration, metal salt precursor ratio, pH, temperature, and reaction time researchers can precisely engineer these physicochemical determinants to tailor nanoparticles for specific biological fates, such as targeted drug delivery, enhanced imaging, or controlled antimicrobial activity.

3. Deconstructing the Theranostic Machinery: Mechanisms of Action

The core of nanomedicine-based theranostics lies in its integrative machinery, where diagnostic and therapeutic functions are not merely co-loaded but engineered into a single, synergistic construct.

3.1. The Diagnostic Lens: Enabling Precision Tumor Imaging

Effective therapy begins with precise localization. Theranostic nanoparticles are engineered to overcome the limitations of conventional contrast agents by providing superior tumor contrast and biologically intelligent sensing.

3.1.1. Modality-Specific Contrast Enhancement (MRI, CT, Photoacoustics)

Nanoparticles are tailored to amplify signals in specific imaging modalities. Superparamagnetic iron oxide nanoparticles (SPIONs) or gadolinium-based nanocarriers enhance T2/T1-weighted magnetic resonance imaging (MRI) by perturbing local proton relaxation. For X-ray computed tomography (CT), gold nanoparticles provide strong X-ray attenuation due to their high atomic number, significantly improving tumor contrast (Popovtzer et al., 2008). Photoacoustic imaging agents, such as organic semiconducting polymers or gold nanorods, absorb near-infrared light and generate ultrasonic waves, offering high-resolution, deep-tissue imaging (Weber et al., 2016).

3.1.2. Tumor Microenvironment-Responsive Actuation and Sensing

Advanced theranostics act as "smart" sensors that activate their diagnostic signal in response to specific tumor microenvironment (TME) cues. This includes pH-responsive nanoprobes that become fluorescent in acidic tumors, or enzyme-activatable probes that release a quenched MRI agent upon encountering overexpressed proteases like matrix metalloproteinases (Lee et al., 2020). This responsive actuation dramatically improves the signal-to-background ratio for precise imaging.

3.2. The Therapeutic Arsenal: Multimodal Oncological Interventions

The therapeutic component of theranostics employs diverse strategies to induce tumor cell death, ranging from direct toxicity to externally triggered, spatially controlled treatments.

3.2.1. Intrinsic Bioactivity and Direct Cytotoxicity

Some nanomaterials possess inherent therapeutic properties. For instance, certain metal oxides (e.g., TiO_2, ZnO) can generate reactive oxygen species (ROS) under specific conditions, leading to oxidative stress in cancer cells (Oberdörster et al., 2005). This intrinsic activity can serve as an adjuvant therapeutic modality.

3.2.2. Enhanced Drug Delivery: Overcoming Pharmacological Barriers

The nanocarrier function of theranostics addresses key limitations of free chemotherapeutics. By encapsulating drugs (e.g., doxorubicin, paclitaxel), these systems leverage the Enhanced Permeability and Retention (EPR) effect for passive tumor targeting and can be functionalized with targeting ligands (e.g., antibodies, peptides) for active targeting (Peer et al., 2007). Stimuli-responsive release (pH, redox) ensures precise drug unloading within the TME (Mura et al., 2013).

3.2.3. Energy-Conversion Therapies: Photothermal and Photodynamic Action

A hallmark of theranostics is the ability to convert externally applied energy into localized therapeutic effects. Photothermal therapy (PTT) employs high-absorption agents (e.g., gold nanoshells, nanorods) to convert near-infrared light into heat, inducing hyperthermic ablation (Hirsch et al., 2003). Photodynamic therapy (PDT) utilizes photosensitizers that, upon light activation, generate cytotoxic singlet oxygen (Dolmans et al., 2003). These therapies offer exceptional spatiotemporal control.

3.3. Synergistic and Combinatorial Paradigms: Overcoming Resistance and Amplifying Efficacy

The true power of theranostics emerges from the deliberate integration of diagnostic and therapeutic mechanisms into synergistic loops. Imaging guides therapy (e.g., delineating tumor margins for PTT), while therapy can be monitored in real-time. Furthermore, combining multiple therapeutic modalities within one platform (e.g., chemo-photothermal therapy) attacks

tumors via orthogonal mechanisms, overcoming single-mode resistance and amplifying overall antitumor efficacy (Li et al., 2022). This combinatorial approach, guided by real-time feedback, represents a paradigm shift towards personalized, adaptive cancer treatment.

4. The In Vivo Odyssey: Pharmacokinetics, Targeting, and Biodistribution

The journey of a nanomaterial from administration to its site of action, and ultimately to its clearance, constitutes a critical determinant of therapeutic efficacy and safety.

4.1. Navigating the Systemic Milieu: Circulation, Passive Accumulation, and the EPR Effect

Upon intravenous administration, nanoparticles are immediately subjected to the dynamic and hostile environment of the systemic circulation. Their hydrodynamic size, surface charge (zeta potential), and surface chemistry are primary factors influencing their pharmacokinetic profile. Hydrophilic coatings, most notably polyethylene glycol (PEG), create a steric barrier that minimizes opsonization the adsorption of plasma proteins that mark particles for phagocytic clearance thereby prolonging circulation half-life (Owens & Peppas, 2006). This "stealth" effect is crucial for allowing nanoparticles to reach their intended target.

For many solid tumors and sites of inflammation, a form of passive targeting known as the Enhanced Permeability and Retention (EPR) effect provides a foundational targeting strategy. The EPR effect exploits the pathological physiology of diseased tissues: leaky, discontinuous vasculature and impaired lymphatic drainage. This allows long-circulating nanoparticles (typically in the size range of 20-200 nm) to extravasate and accumulate preferentially within the tumor interstitium (Matsumura & Maeda, 1986) Passive diffusion and convection across the permeable tumor endothelium enable the extravasation of long-circulating Stealth™ nanoparticles into the tumor interstitium (Figure 1). However, the clinical homogeneity and reliability of the EPR effect have been questioned, as it exhibits significant variability between cancer types, individual patients, and even within different regions of the same tumor (Golombek et al., 2018). Consequently, while a cornerstone of nanomedicine, reliance on passive targeting alone is often insufficient.

Figure 2

Long-circulating Stealth™ nanoparticles passively leak out of the tumor's permeable blood vessels and accumulate in the tumor interstitium.



4.2. Towards Precision: Active Targeting Strategies via Surface Functionalization

To enhance specificity and cellular uptake beyond the EPR effect, active targeting strategies are employed. This involves the conjugation of targeting ligands such as antibodies, antibody fragments, peptides, aptamers, or small molecules (e.g., folic acid) to the nanoparticle surface. These ligands selectively bind to receptors or antigens that are overexpressed on the surface of target cells (e.g., cancer cells, endothelial cells of angiogenic vessels) (Byrne et al., 2008).

The paradigm is often described as "binding and entry." Successful ligand-receptor engagement can: (1) increase nanoparticle accumulation at the target site through affinity-based retention, (2) trigger receptor-mediated endocytosis for efficient cellular internalization, and (3) potentially enable sub-cellular targeting. It is critical to note that active targeting is generally considered a multistage process, where prolonged circulation (via stealth coatings) enables nanoparticles to reach the target vasculature, followed by ligand-mediated binding to overcome biological barriers for final delivery (Wilhelm et al., 2016). The choice of ligand involves a trade-off between targeting affinity, immunogenicity, stability, and the density of conjugation, which must be optimized to avoid the "binding-site barrier" effect where nanoparticles bind too strongly at the periphery of a tumor, preventing deep penetration.

4.3. Cellular Entry and Intracellular Trafficking: From Membrane Engagement to Organelle Delivery

Once at the target cell, nanoparticles must traverse the plasma membrane. The primary mechanism for internalization of targeted nanoparticles is energy-dependent endocytosis. The specific pathway including clathrin-mediated endocytosis, caveolae-mediated uptake, macropinocytosis, or other mechanisms dictates the subsequent intracellular trafficking fate and is influenced by nanoparticle size, shape, surface chemistry, and the receptor engaged (Sahay et al., 2010).

Following endocytosis, nanoparticles are typically trafficked through the endosomal-lysosomal system. For many therapeutic cargos (e.g., nucleic acids, proteins), this acidic and enzyme-rich compartment is degradative and represents a major barrier to efficacy. Therefore, a key design challenge is incorporating "endosomal escape" functionalities. Strategies include the use of cationic lipids or polymers (e.g., PEI) that buffer the endosomal pH, leading to osmotic swelling and rupture (the "proton sponge" effect), or membrane-disruptive peptides (Varkouhi et al., 2011). For organelle-specific delivery, such as to the mitochondria or nucleus, additional secondary targeting motifs (e.g., mitochondrial-penetrating peptides, nuclear localization sequences) must be incorporated to guide the cargo after escape from the endosome.

4.4. Clearance Pathways and Long-Term Biocompatibility Considerations

The final act of the in vivo odyssey is clearance, which directly impacts long-term biocompatibility and potential toxicity. Nanoparticles that are not biodegradable can persist in the body, leading to chronic inflammatory

responses or organ dysfunction. The primary clearance routes are renal (kidney) and hepatobiliary (liver).

Renal clearance is typically restricted to very small nanoparticles or degradation products (<5-6 nm in hydrodynamic diameter) that can pass through the glomerular basement membrane. Most larger nanoparticles are eventually cleared by the mononuclear phagocyte system (MPS), primarily in the liver (Kupffer cells) and spleen (Suk et al., 2016). This MPS capture, while a hurdle for drug delivery, can be leveraged for diagnostic or therapeutic applications targeting these organs.

Biodegradability is a paramount design principle for clinical translation. Materials like poly(lactic-co-glycolic acid) (PLGA), lipids, and certain silica formulations are designed to degrade into metabolizable or excretable components. The kinetics of degradation, the nature of degradation by-products, and their potential for eliciting immune or oxidative stress responses must be thoroughly characterized (Fadeel et al., 2018). Furthermore, the phenomenon of the "accelerated blood clearance" (ABC) effect, where repeated administration of PEGylated nanoparticles can trigger anti-PEG IgM responses and rapid clearance of subsequent doses, underscores the need for advanced, immune-stealth materials for chronic therapies (Ishida & Kiwada, 2008). A comprehensive understanding of clearance mechanisms and long-term biodistribution is essential for ensuring the safety profile of any nanomedicine.

5. Confronting the Translational Chasm: Critical Bottlenecks and Unresolved Challenges

The journey of phytonanomedicines from foundational research to clinical application is fraught with a significant translational chasm. Despite promising in vitro and preliminary in vivo data, numerous systemic bottlenecks impede their progression, reflecting broader challenges in nanomedicine while presenting unique complexities due to their botanical origins.

5.1. The Reproducibility Quandary: Standardizing the Phyto-Nano Interface

A primary bottleneck is the lack of reproducibility in phytonanoparticle synthesis. Unlike synthetic nanoparticles, phytonanoparticles are derived from extracts containing hundreds of phytochemicals, whose composition varies with plant genotype, geographical origin, season, and extraction protocol. This biological variability directly impacts nanoparticle characteristics like size, charge, surface chemistry, and consequently, biological activity (Mohanraj & Chen, 2006; Kroll et al., 2009). The "green synthesis" of metallic nanoparticles (e.g., using plant extracts to reduce metal ions) faces similar issues, where slight changes in pH, temperature, or extract concentration yield disparate products (Iravani, 2011). The field urgently needs standardized operating procedures (SOPs) for source material validation, extraction, and synthesis, alongside robust analytical characterization (size, polydispersity index, zeta potential, morphology, and compound loading) as a minimum reporting standard (Foulkes et al., 2020). Without such standardization, comparing studies and replicating results across laboratories becomes impossible, eroding scientific confidence and hindering regulatory review.

5.2. Decoding Complexity: The Dynamic Protein Corona and Immune System Crosstalk

Upon entering a biological fluid (e.g., blood), nanoparticles are immediately coated by a layer of proteins, forming the "protein corona." This corona is dynamic and dictates the nanoparticle's biological identity, influencing its cellular uptake, biodistribution, clearance, and immunogenicity (Monopoli et al., 2012). For phytonanoparticles, the corona is exceptionally complex. The surface may present both the core material (e.g., a polymeric or metallic core) and adsorbed phytochemicals, creating a heterogenous interface that interacts unpredictably with plasma proteins (Ke et al., 2017). Furthermore, many phytochemicals (e.g., curcumin, resveratrol) are known immunomodulators. When nano-encapsulated, their interaction with immune cells (e.g., macrophages, dendritic cells) can be altered, potentially triggering unintended immunostimulation or suppression (Liu et al., 2024). The crosstalk between the protein corona, the phytochemical payload, and the host immune system remains a critical "black box." A lack of understanding in this area prevents rational design of phytonanoparticles with predictable in vivo behavior and safe immunological profiles.

5.3. From Benchtop to Bedside: Scalability, Regulatory Landscapes, and Commercial Viability

Scaling up laboratory synthesis to Good Manufacturing Practice (GMP) standards for clinical trials is a formidable challenge. Batch-to-batch consistency, a requirement for pharmaceuticals, is difficult to achieve with biological starting materials (Hussain, 2020). The regulatory pathway for phytonanomedicines is also ambiguous. They fall into a hybrid category, potentially reviewed as combination products (botanical drug + device/delivery system) by agencies like the FDA and EMA. Regulators require definitive characterization of both the active pharmaceutical ingredient (the phytocomplex or specific compound) and the nanoparticle component, a task complicated by phytochemical complexity (Tibbitt et al., 2016). Furthermore, establishing a compelling cost-benefit analysis is difficult. The added cost and complexity of nano-formulation must be justified by significantly superior efficacy or reduced toxicity compared to conventional phytopharmaceuticals or existing synthetic drugs, a claim requiring extensive and expensive clinical validation (Anselmo & Mitragotri, 2016).

5.4. Inherent Therapeutic Limitations: Penetration Depth, Heterogeneity, and Potential Off-Target Effects

Despite their targeting potential, phytonanoparticles face inherent physical and biological barriers. In solid tumors, for example, dysfunctional vasculature and dense extracellular matrix can limit penetration depth, confining nanoparticles to perivascular regions, a phenomenon known as heterogeneous distribution (Nichols & Bae, 2014). The "enhanced permeability and retention" (EPR) effect, a cornerstone of passive tumor targeting, is now recognized to be highly variable across tumor types and patients, further complicating efficacy predictions (Prabhakar et al., 2013). Additionally, while nano-encapsulation can reduce systemic toxicity of phytochemicals, off-target effects remain a concern.

Accumulation in organs of the mononuclear phagocyte system (liver, spleen) can lead to long-term sequestration and potential organ-specific toxicity (Wilhelm et al., 2016). The potential for unintended interactions with biological barriers (e.g., the gut microbiome for oral formulations, the blood-brain barrier) also requires deeper investigation to fully de-risk these novel therapeutics.

Figure 3

Translational challenges in phytonanomedicine, highlighting key bottlenecks—reproducibility, immune interactions, scalability, and therapeutic limitations—and future strategies to enable clinical translation.



6. Envisioning the Future: Pioneering Trajectories for Clinical Translation

To bridge the translational chasm, a paradigm shift is required from serendipitous discovery to rational design, and from one-size-fits-all to personalized, intelligent systems. The future of phytonanomedicine lies in converging cutting-edge nanotechnology, digital tools, and precision medicine principles to create transformative, clinically viable therapies.

6.1. Next-Generation Intelligent Nanoplatforms: Stimuli-Responsive, Adaptive, and Immuno-Engineered Systems

Moving beyond passive delivery, the future lies in "smart" phytonanoplatforms that actively respond to the unique pathophysiological cues of the disease microenvironment. Stimuli-responsive systems are engineered to release their phytotherapeutic payload specifically at the target site. These can be triggered by endogenous signals like the acidic tumor pH, overexpressed enzymes (e.g., matrix metalloproteinases), or elevated redox potential (GFLutathione) (Mura et al., 2013). Externally triggered systems using near-infrared light (NIR) or alternating magnetic fields offer spatiotemporal control, enhancing precision and reducing off-target effects (Li et al., 2020). Furthermore, immuno-engineering the phyto-nano interface presents a powerful strategy. By decorating nanoparticles with specific phytochemicals (e.g., saponins, polysaccharides) known as adjuvants, or by designing biomimetic coatings from cell membranes, we can actively modulate immune responses either evading immune clearance for longer circulation or engaging immune cells for enhanced cancer immunotherapy or vaccine development (Zhang et al., 2021). These adaptive systems will transform phytonanomedicines from simple carriers into active, participating therapeutic agents.

6.2. Convergence with Digital Tools: AI-Driven Design and Omics-Guided Characterization

The inherent complexity of phytonanomedicines makes them ideal candidates for analysis and optimization through artificial intelligence (AI) and machine learning (ML). AI-driven design can accelerate the discovery process by predicting optimal combinations of plant extracts, synthesis conditions, and nanoparticle parameters (e.g., polymer, lipid composition) to achieve desired properties (size, drug release profile, targeting efficiency) (Gormley, 2024). ML models trained on large datasets of nanoparticle-protein corona interactions can help predict in vivo fate and immunogenicity. Concurrently, omics technologies (proteomics, lipidomics, metabolomics) are crucial for comprehensive characterization. Proteomics can decode the dynamic protein corona, while metabolomics can track the fate of the phytochemical payload and its metabolites within biological systems, providing a systems-level understanding of efficacy and safety (Docter et al., 2015). This digital-physical convergence will enable a shift from empirical tuning to predictive, rational design.

6.3. Personalized Phyto-Nanomedicine: Integration with Biomarkers and Patient-Specific Therapies

The future clinical application of phytonanomedicines will likely be in stratified or personalized medicine. Patient heterogeneity in disease pathology (e.g., tumor receptor expression), physiological barriers, and immune status means a single formulation will not be optimal for all. The integration of companion biomarkers is essential. These could be imaging biomarkers to confirm EPR effect presence, or molecular biomarkers (e.g., from liquid biopsies) to identify patients most likely to respond to a specific phytochemical pathway modulation (e.g., NF-κB, STAT3 inhibition) (Lammers et al., 2012). On a more advanced front, patient-specific therapies could involve using autologous cell membranes for nanoparticle coating to enhance homotypic targeting, or even ex vivo priming of immune cells with phytonanoparticles before reinfusion. This approach moves treatment from a generalized strategy to one tailored to an individual's unique disease biology.

6.4. Sustainable Translation: A Roadmap Integrating Green Chemistry, Robust Manufacturing, and Clinical Trial Design

For successful translation, technical innovation must be coupled with sustainable development practices. Green chemistry principles (e.g., atom economy, safer solvents, renewable feedstocks) should be embedded from the earliest design phase to ensure environmental sustainability aligns with the "green" synthesis ethos (Anastas & Eghbali, 2010). To address scalability, continuous manufacturing platforms (e.g., microfluidic reactors) must be adopted to replace traditional batch synthesis. These systems offer superior control over critical quality attributes, ensuring reproducibility and facilitating Quality-by-Design (QbD) approaches mandated for regulatory approval (Danaei et al., 2018).

Finally, innovative clinical trial designs are needed. Adaptive trial designs, basket trials (testing one nanoparticle against multiple diseases with a common biomarker), and the inclusion of robust pharmacokinetic/pharmacodynamic (PK/PD) and imaging biomarkers in early-phase trials can accelerate clinical evaluation, reduce costs, and provide richer data to guide development (Kimmelman & London, 2015). This integrated roadmap from eco-conscious design to robust production and efficient clinical validation is critical for bringing phytonanomedicines to the clinic sustainably and successfully.

CONCLUSION

Phytonanomedicine emerges as a compelling and sustainable frontier in oncology, synthesizing the therapeutic heritage of medicinal plants with the precision of nanotechnology. The green synthesis pathway offers an eco-friendly method to produce a versatile arsenal of nanostructures with inherent biocompatibility and multifunctional capabilities. As detailed, these platforms can be engineered to serve as sophisticated theranostic agents, combining targeted diagnostic imaging with multimodal therapeutic interventions such as enhanced drug delivery, photothermal ablation, and combinatorial therapies. This synergy aims to overcome the limitations of conventional treatments by improving specificity, efficacy, and real-time monitoring.

However, the path from laboratory innovation to clinical bedside is fraught with systemic challenges. The reproducibility of synthesis, the unpredictable biological interactions dictated by the dynamic protein corona, the hurdles in scalable manufacturing, and the heterogeneity of the tumor microenvironment constitute significant translational bottlenecks. To navigate these, a paradigm shift is imperative. The future of phytonanomedicine lies in the development of intelligent, stimuli-responsive systems, the application of AI and omics for predictive design and characterization, and the stratification of therapies guided by patient-specific biomarkers. Success will depend on an integrated translational roadmap that rigorously addresses standardization, mechanistic understanding of biocompatibility, and navigates the regulatory landscape through quality-by-design principles. By confronting these challenges with interdisciplinary innovation, phytonanomedicine holds significant potential to evolve from a promising concept into a mainstream, personalized, and effective modality in the global fight against cancer.

REFERENCES

Ahmad, S., Munir, S., Zeb, N., Ullah, A., Khan, B., Ali, J., Bilal, M., Omer, M., Alamzeb, M., Salman, S. M., & Ali, S. (2019). Green nanotechnology: a review on green synthesis of silver nanoparticles—an ecofriendly approach. *International Journal of Nanomedicine*, *14*, 5087-5107. https://doi.org/10.2147/ijn.s200254

Ahmed, S., Ahmad, M., Swami, B. L., & Ikram, S. (2016). A review on plants extract mediated synthesis of silver nanoparticles for antimicrobial applications: A green expertise. *Journal of Advanced Research*, *7*(1), 17-28. https://doi.org/10.1016/j.jare.2015.02.007

Anastas, P., & Eghbali, N. (2010). Green chemistry: Principles and practice. *Chem. Soc. Rev*, *39*(1), 301-312. https://doi.org/10.1039/b918763b

Anselmo, A. C., & Mitragotri, S. (2016). Nanoparticles in the clinic. *Bioengineering & Translational Medicine*, *1*(1), 10-29. https://doi.org/10.1002/btm2.10003

Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. *Advanced Drug Delivery Reviews*, *60*(15), 1615-1626. https://doi.org/10.1016/j.addr.2008.08.005

Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018). Impact of particle size and Polydispersity index on the clinical applications of Lipidic Nanocarrier systems. *Pharmaceutics*, *10*(2), 57. https://doi.org/10.3390/pharmaceutics10020057

Docter, D., Westmeier, D., Markiewicz, M., Stolte, S., Knauer, S. K., & Stauber, R. H. (2015). The nanoparticle biomolecule corona: Lessons learned – challenge accepted? *Chemical Society Reviews*, *44*(17), 6094-6121. https://doi.org/10.1039/c5cs00217f

Dolmans, D. E., Fukumura, D., & Jain, R. K. (2003). Photodynamic therapy for cancer. *Nature Reviews Cancer*, *3*(5), 380-387. https://doi.org/10.1038/nrc1071

Fadeel, B., Bussy, C., Merino, S., Vázquez, E., Flahaut, E., Mouchet, F., Evariste, L., Gauthier, L., Koivisto, A. J., Vogel, U., Martín, C., Delogu, L. G., Buerki-Thurnherr, T., Wick, P., Beloin-Saint-Pierre, D., Hischier, R., Pelin, M., Candotto Carniel, F., Tretiach, M., … Bianco, A. (2018). Safety assessment of graphene-based materials: Focus on human health and the environment. *ACS Nano*, *12*(11), 10582-10620. https://doi.org/10.1021/acsnano.8b04758

Foulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C. (2020). The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives. *Biomaterials Science*, *8*(17), 4653-4664. https://doi.org/10.1039/d0bm00558d

Fratoddi, I. (2017). Hydrophobic and hydrophilic AU and Ag nanoparticles. Breakthroughs and perspectives. *Nanomaterials*, *8*(1), 11. https://doi.org/10.3390/nano8010011

Garg, D., Sarkar, A., Chand, P., Bansal, P., Gola, D., Sharma, S., Khantwal, S., Surabhi, Mehrotra, R., Chauhan, N., & Bharti, R. K. (2020). Synthesis of silver nanoparticles utilizing various biological systems: Mechanisms and applications—a review. *Progress in Biomaterials*, *9*(3), 81-95. https://doi.org/10.1007/s40204-020-00135-2

Golombek, S. K., May, J., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018). Tumor targeting via EPR: Strategies to enhance patient responses. *Advanced Drug Delivery Reviews*, *130*, 17-38. https://doi.org/10.1016/j.addr.2018.07.007

Gormley, A. J. (2024). Machine learning in drug delivery. *Journal of Controlled Release*, *373*, 23-30. https://doi.org/10.1016/j.jconrel.2024.06.045

Hirsch, L. R., Stafford, R. J., Bankson, J. A., Sershen, S. R., Rivera, B., Price, R. E., Hazle, J. D., Halas, N. J., & West, J. L. (2003). Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. *Proceedings of the National Academy of Sciences*, *100*(23), 13549-13554. https://doi.org/10.1073/pnas.2232479100

Hussain, W.; Ullah, M.; Dastagir, G.; Badshah, L. Quantitative ethnobotanical appraisal of medicinal plants used by inhabitants of lower Kurram, Kurram agency, Pakistan. Avicenna J. Phytomed. 2018, 8, 313–329.

Hussain, S. (2015). Nanomedicine for treatment of lung cancer. *Advances in Experimental Medicine and Biology*, 137-147. https://doi.org/10.1007/978-3-319-24932-2_8

Iqbal, J., Abbasi, B. A., Mahmood, T., Kanwal, S., Ali, B., Shah, S. A., & Khalil, A. T. (2017). Plant-derived anticancer agents: A green anticancer approach. *Asian Pacific Journal of Tropical Biomedicine*, *7*(12), 1129-1150. https://doi.org/10.1016/j.apjtb.2017.10.016

Iravani, S. (2011). Green synthesis of metal nanoparticles using plants. *Green Chemistry*, *13*(10), 2638. https://doi.org/10.1039/c1gc15386b

Ishida, T., & Kiwada, H. (2008). Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. *International Journal of Pharmaceutics*, *354*(1-2), 56-62. https://doi.org/10.1016/j.ijpharm.2007.11.005

Lee, J., Kim, H. Y., Zhou, H., Hwang, S., Koh, K., Han, D., & Lee, J. (2011). Green synthesis of phytochemical-stabilized AU nanoparticles under ambient conditions and their biocompatibility and antioxidative activity. *Journal of Materials Chemistry*, *21*(35), 13316. https://doi.org/10.1039/c1jm11592h

Kashkooli, F. M., Soltani, M., Momeni, M. M., & Rahmim, A. (2021). Enhanced drug delivery to solid tumors via drug-loaded Nanocarriers: An image-based computational framework. *Frontiers in Oncology*, *11*. https://doi.org/10.3389/fonc.2021.655781

Kashkooli, F. M., Soltani, M., & Souri, M. (2020). Controlled anti-cancer drug release through advanced nano-drug delivery systems: Static and dynamic targeting strategies. *Journal of Controlled Release*, *327*, 316-349. https://doi.org/10.1016/j.jconrel.2020.08.012

Ke, P. C., Lin, S., Parak, W. J., Davis, T. P., & Caruso, F. (2017). A decade of the protein Corona. *ACS Nano*, *11*(12), 11773-11776. https://doi.org/10.1021/acsnano.7b08008

Khan, S. A., Shahid, S., & Lee, C. (2020). Green synthesis of gold and silver nanoparticles using leaf extract of Clerodendrum inerme; Characterization, antimicrobial, and antioxidant activities. *Biomolecules*, *10*(6), 835. https://doi.org/10.3390/biom10060835

Kharissova, O. V., Dias, H. R., Kharisov, B. I., Pérez, B. O., & Pérez, V. M. (2013). The greener synthesis of nanoparticles. *Trends in Biotechnology*, *31*(4), 240-248. https://doi.org/10.1016/j.tibtech.2013.01.003

Kimmelman, J., & London, A. J. (2015). The structure of clinical translation: *Efficiency, information, and Ethics*. *Hastings Center Report*, *45*(2), 27-39. https://doi.org/10.1002/hast.433

Kroll, D. J., Shaw, H. S., & Oberlies, N. H. (2007). Milk Thistle nomenclature: Why it matters in cancer research and pharmacokinetic studies. *Integrative Cancer Therapies*, *6*(2), 110-119. https://doi.org/10.1177/1534735407301825

Lammers, T., Rizzo, L. Y., Storm, G., & Kiessling, F. (2012). Personalized Nanomedicine. *Clinical Cancer Research*, *18*(18), 4889-4894. https://doi.org/10.1158/1078-0432.ccr-12-1414

Lane, L. A. (2020). Physics in nanomedicine: Phenomena governing the *in vivo* performance of nanoparticles. *Applied Physics Reviews*, *7*(1). https://doi.org/10.1063/1.5052455

Lee, M. H., Sharma, A., Chang, M. J., Lee, J., Son, S., Sessler, J. L., Kang, C., & Kim, J. S. (2018). Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics. *Chemical Society Reviews*, *47*(1), 28-52. https://doi.org/10.1039/c7cs00557a

Leng, F., Liu, F., Yang, Y., Wu, Y., & Tian, W. (2018). Strategies on Nanodiagnostics and Nanotherapies of the three common cancers. *Nanomaterials*, *8*(4), 202. https://doi.org/10.3390/nano8040202

Li, J., & Kataoka, K. (2020). Chemo-physical strategies to advance the *in Vivo* functionality of targeted Nanomedicine: The next generation. *Journal of the American Chemical Society*, *143*(2), 538-559. https://doi.org/10.1021/jacs.0c09029

Li, J., & Kataoka, K. (2020). Chemo-physical strategies to advance the *in Vivo* functionality of targeted Nanomedicine: The next generation. *Journal of the American Chemical Society*, *143*(2), 538-559. https://doi.org/10.1021/jacs.0c09029

Liu, C., Yu, Y., Fang, L., Wang, J., Sun, C., Li, H., Zhuang, J., & Sun, C. (2023). Plant-derived nanoparticles and plant virus nanoparticles: Bioactivity, health management, and delivery potential. *Critical Reviews in Food Science and Nutrition*, *64*(24), 8875-8891. https://doi.org/10.1080/10408398.2023.2204375

Makarov, V. V., Love, A. J., Sinitsyna, O. V., Makarova, S. S., Yaminsky, I. V., Taliansky, M. E., & Kalinina, N. O. (2014). "Green" Nanotechnologies: Synthesis of metal nanoparticles using plants. *Acta Naturae*, *6*(1), 35-44. https://doi.org/10.32607/20758251-2014-6-1-35-44

Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research, 46(12 Part 1), 6387-6392.

Mittal, A. K., Chisti, Y., & Banerjee, U. C. (2013). Synthesis of metallic nanoparticles using plant extracts. *Biotechnology Advances*, *31*(2), 346-356. https://doi.org/10.1016/j.biotechadv.2013.01.003

Mohanraj, V. J., & Chen, Y. (2007). Nanoparticles - A review. *Tropical Journal of Pharmaceutical Research*, *5*(1). https://doi.org/10.4314/tjpr.v5i1.14634

Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012). Biomolecular coronas provide the biological identity of nanosized materials. *Nature Nanotechnology*, *7*(12), 779-786. https://doi.org/10.1038/nnano.2012.207

Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. *Nature Materials*, *12*(11), 991-1003. https://doi.org/10.1038/nmat3776

Nichols, J. W., & Bae, Y. H. (2012). Odyssey of a cancer nanoparticle: From injection site to site of action. *Nano Today*, *7*(6), 606-618. https://doi.org/10.1016/j.nantod.2012.10.010

Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005). Nanotoxicology: An emerging discipline evolving from studies of Ultrafine particles. *Environmental Health Perspectives*, *113*(7), 823-839. https://doi.org/10.1289/ehp.7339

OWENSIII, D., & PEPPAS, N. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. *International Journal of Pharmaceutics*, *307*(1), 93-102. https://doi.org/10.1016/j.ijpharm.2005.10.010

Patra, S., Mukherjee, S., Barui, A. K., Ganguly, A., Sreedhar, B., & Patra, C. R. (2015). Green synthesis, characterization of gold and silver nanoparticles and their potential application for cancer therapeutics. *Materials Science and Engineering: C*, *53*, 298-309. https://doi.org/10.1016/j.msec.2015.04.048

Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotechnology*, *2*(12), 751-760. https://doi.org/10.1038/nnano.2007.387

Popovtzer, R., Agrawal, A., Kotov, N. A., Popovtzer, A., Balter, J., Carey, T. E., & Kopelman, R. (2008). Targeted gold nanoparticles enable molecular CT imaging of cancer. *Nano Letters*, *8*(12), 4593-4596. https://doi.org/10.1021/nl8029114

Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013). Challenges and key considerations of the enhanced permeability and retention effect for Nanomedicine drug delivery in oncology. *Cancer Research*, *73*(8), 2412-2417. https://doi.org/10.1158/0008-5472.can-12-4561

Mukherjee, S., B, V., Prashanthi, S., Bangal, P. R., Sreedhar, B., & Patra, C. R. (2013). Potential therapeutic and diagnostic applications of one-step in situ biosynthesized gold nanoconjugates (2-in-1 system) in cancer treatment. *RSC Advances*, *3*(7), 2318. https://doi.org/10.1039/c2ra22299j

Mukherjee, S., Chowdhury, D., Kotcherlakota, R., Patra, S., B, V., Bhadra, M. P., Sreedhar, B., & Patra, C. R. (2014). Potential Theranostics application of bio-synthesized silver nanoparticles (4-in-1 system). *Theranostics*, *4*(3), 316-335. https://doi.org/10.7150/thno.7819

Mukherjee, S., Sushma, V., Patra, S., Barui, A. K., Bhadra, M. P., Sreedhar, B., & Patra, C. R. (2012). Green chemistry approach for the synthesis and stabilization of biocompatible gold nanoparticles and their potential applications in cancer therapy. *Nanotechnology*, *23*(45), 455103. https://doi.org/10.1088/0957-4484/23/45/455103

Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010). Endocytosis of nanomedicines. *Journal of Controlled Release*, *145*(3), 182-195. https://doi.org/10.1016/j.jconrel.2010.01.036

Sargazi, S., Laraib, U., Er, S., Rahdar, A., Hassanisaadi, M., Zafar, M. N., Díez-Pascual, A. M., & Bilal, M. (2022). Application of green gold nanoparticles in cancer therapy and diagnosis. *Nanomaterials*, *12*(7), 1102. https://doi.org/10.3390/nano12071102

Siddiqi, K. S., Husen, A., & Rao, R. A. (2018). A review on biosynthesis of silver nanoparticles and their biocidal properties. *Journal of Nanobiotechnology*, *16*(1). https://doi.org/10.1186/s12951-018-0334-5

Stephen, B. J., Suchanti, S., Mishra, R., & Singh, A. (2020). Cancer nanotechnology in medicine: A promising approach for cancer detection and diagnosis. *Critical Reviews™ in Therapeutic Drug Carrier Systems*, *37*(4), 375-405. https://doi.org/10.1615/critrevtherdrugcarriersyst.2020033263

Stylianopoulos, T., & Jain, R. K. (2015). Design considerations for nanotherapeutics in oncology. *Nanomedicine: Nanotechnology, Biology and Medicine*, *11*(8), 1893-1907. https://doi.org/10.1016/j.nano.2015.07.015

Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016). PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Advanced Drug Delivery Reviews*, *99*, 28-51. https://doi.org/10.1016/j.addr.2015.09.012

Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016). Emerging frontiers in drug delivery. *Journal of the American Chemical Society*, *138*(3), 704-717. https://doi.org/10.1021/jacs.5b09974

Tinajero-Díaz, E., Salado-Leza, D., Gonzalez, C., Martínez Velázquez, M., López, Z., Bravo-Madrigal, J., Knauth, P., Flores-Hernández, F. Y., Herrera-Rodríguez, S. E., Navarro, R. E., Cabrera-Wrooman, A., Krötzsch, E., Carvajal, Z. Y., & Hernández-Gutiérrez, R. (2021). Green metallic nanoparticles for cancer therapy: Evaluation models and cancer applications. *Pharmaceutics*, *13*(10), 1719. https://doi.org/10.3390/pharmaceutics13101719

Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011). Endosomal escape pathways for delivery of biologicals. *Journal of Controlled Release*, *151*(3), 220-228. https://doi.org/10.1016/j.jconrel.2010.11.004

Verma, S. K., Das, A. K., Gantait, S., Panwar, Y., Kumar, V., & Brestic, M. (2021). Green synthesis of carbon-based nanomaterials and their applications in various sectors: A topical review. *Carbon Letters*, *32*(2), 365-393. https://doi.org/10.1007/s42823-021-00294-7

Weber, J., Beard, P. C., & Bohndiek, S. E. (2016). Contrast agents for molecular photoacoustic imaging. *Nature Methods*, *13*(8), 639-650. https://doi.org/10.1038/nmeth.3929

Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. (2016). Analysis of nanoparticle delivery to tumours. *Nature Reviews Materials*, *1*(5). https://doi.org/10.1038/natrevmats.2016.14

World Health Organization. The Top 10 Causes of Death. 2019. Available online: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed on 22 February 2022).

Zhang, L., Wang, Z., Zhang, Y., Cao, F., Dong, K., Ren, J., & Qu, X. (2021). Erythrocyte membrane cloaked metal-organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy. ACS Nano, 15(12), 19067-19078. https://doi.org/10.1021/acsnano.8b05200.s001